{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-039409","form_type":"8-K","ticker":"CRBP","cik":"0001595097","company_name":"Corbus Pharmaceuticals Holdings, Inc.","filed_at":"2023-08-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.478630+00:00","generated_at":"2026-06-12T02:00:38.074276+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Corbus Q2 net loss $8.8M vs $13.2M YoY; cash $36.6M; pipeline on track","bullets":["Net loss of $8.8M ($2.05 diluted EPS) compared to $13.2M ($3.18) in Q2 2022; operating expenses down $4.1M.","Cash, cash equivalents and investments $36.6M as of June 30, 2023; expected to fund operations through Q2 2024.","CRB-701 Phase 1 dose escalation ahead of schedule in China; completion expected Q4 2023; US trial start accelerated to Q1 2024.","Preliminary PK data for CRB-701 shows longer half-life and lower free MMAE vs published PADCEV data.","CRB-601 IND submission on track for Q4 2023; first patient in Phase 1 expected H1 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-039409","json":"https://secwatch.observer/filing/0000950170-23-039409.json","markdown":"https://secwatch.observer/filing/0000950170-23-039409.md","text":"https://secwatch.observer/filing/0000950170-23-039409.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1595097/000095017023039409/0000950170-23-039409-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1595097/000095017023039409/crbp-20230808.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-12T02:00:38.074276+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"32fcfe2110f0640055e1e80ce8145136a6c8545d","claim":"Corbus Pharmaceuticals Holdings, Inc. reported the three months ended June 30, 2023 results: net income net loss of approximately $8.8 million, or a net loss per diluted share of $2.05, EPS $2.05.","evidence_excerpt":"The Company reported a net loss of approximately $8.8 million, or a net loss per diluted share of $2.05, for the three months ended June 30, 2023","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1595097/000095017023039409/0000950170-23-039409-index.htm","confidence":1.0,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the three months ended June 30, 2023"},{"label":"Net income","value":"net loss of approximately $8.8 million, or a net loss per diluted share of $2.05"},{"label":"EPS","value":"$2.05"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}